Overview
The purpose of this study is to assess if Six-Dimensional Magnetic Resonance Imaging (6D-MRI) is effective in predicting outcomes in patients with pancreatic ductal adenocarcinoma (PDAC).
Description
The overarching goal of this pilot study is to evaluate the usefulness of a novel Magnetic Resonance Imaging (MRI) approach, which measure properties of tumor microenvironment (i.e. vascularity, fibrosis), to predict PDAC response to neoadjuvant therapy (NAT).
Eligibility
Inclusion Criteria:
- Pancreatic cancer patients (with resectable or borderline resectable or locally advanced tumors) who will undergo neoadjuvant chemotherapy
- Patients able to undergo at least two sets of MRI sessions
- Access to a device that has the capability to sync to the Fitbit (or access to a family member's, caregiver's, or friend's device)
Exclusion Criteria:
- Patients who have previously been treated for PDAC
- Patients unable to undergo MRI exam w/contrast
- Patients with metastatic pancreatic cancer visualized on index diagnostic imaging
- Patients with certain metallic implants
- Patients experiencing claustrophobia